RxDoctor Payments Data

Stephen Levy, MD

Interventional Cardiology · Florham Park, NJNPI 1316947856

Payments from drug & device makers

$2,052in general payments, 2019–2025

Across 148 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$602
  • Novartis$332
  • Boehringer Ingelheim$261
  • E.r. Squibb & Sons, L.L.C.$212
  • Johnson & Johnson$147
  • Amarin Pharma, Inc.$105
  • plus $392 from 12 others

What the payments were for

  • Food & beverage$2,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,052 in reported general payments places this provider in the 15th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$213,704
Medicare patients
429
Services billed
2,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$213,813
XareltoRivaroxaban33$39,039
EntrestoSacubitril/Valsartan23$28,276
Repatha SureclickEvolocumab11$16,220
Metoprolol Succinate516$7,624
EdarbiAzilsartan Medoxomil17$6,222
Ranolazine ErRanolazine44$4,715
Pitavastatin Calcium11$4,157
Rosuvastatin Calcium350$3,899
BystolicNebivolol Hcl14$3,089
Atorvastatin Calcium294$2,441
Omega-3 Acid Ethyl Esters24$2,288
Amiodarone Hcl16$2,194
Ezetimibe74$2,094
Icosapent Ethyl15$1,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$213,813179 claims
Johnson & JohnsonXarelto$147$39,03933 claims
NovartisEntresto$332$28,27623 claims
Arbor Pharmaceuticals, Inc.Edarbi$27$6,22217 claims
Kowa Pharmaceuticals America, Inc.Bystolic$57$3,08914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Florham Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →